Scarica l'app Stockscreener
19.75
2.27%
-0.47
Dopo l'orario di chiusura:
19.75
Enliven Therapeutics Inc Borsa (ELVN) Ultime notizie
RSI Suggests Rebound May Be Near in Enliven Therapeutics Inc.2025 Investor Takeaways & Smart Allocation Stock Tips - classian.co.kr
Using AI based signals to follow Enliven Therapeutics Inc.Weekly Risk Report & AI Forecast Swing Trade Picks - Newser
Multi factor analysis applied to Enliven Therapeutics Inc.2025 Market Outlook & Risk Managed Investment Signals - Newser
Is Enliven Therapeutics Inc. stock bottoming outPortfolio Value Report & Risk Controlled Swing Alerts - Newser
What MACD signals say about Enliven Therapeutics Inc.Earnings Beat & Growth Focused Stock Reports - Newser
What is Lifesci Capital’s Estimate for ELVN Q3 Earnings? - Defense World
How to use Fibonacci retracement on Enliven Therapeutics Inc.July 2025 Market Mood & Real-Time Volume Trigger Notifications - Newser
Combining price and volume data for Enliven Therapeutics Inc.2025 Macro Impact & Free Accurate Trade Setup Notifications - Newser
Technical signs of recovery in Enliven Therapeutics Inc.Market Sentiment Report & Daily Momentum Trading Reports - Newser
Should you wait for a breakout in Enliven Therapeutics Inc.2025 Price Targets & Expert Curated Trade Setup Alerts - Newser
Will Enliven Therapeutics Inc. stock go up in YEARBreakout Watch & Growth-Oriented Investment Plans - thegnnews.com
Using economic indicators to assess Enliven Therapeutics Inc. potentialJuly 2025 Pullbacks & Capital Efficient Trade Techniques - Newser
Chart overlay techniques for tracking Enliven Therapeutics Inc.July 2025 Market Mood & Pattern Based Trade Signal System - Newser
Can Enliven Therapeutics Inc. rally from current levels2025 Investor Takeaways & Verified Trade Idea Suggestions - Newser
How to integrate Enliven Therapeutics Inc. into portfolio analysis toolsDip Buying & Low Drawdown Trading Techniques - Newser
Analyzing Enliven Therapeutics Inc. with risk reward ratio chartsQuarterly Profit Summary & Real-Time Stock Movement Alerts - Newser
Can volume confirm reversal in Enliven Therapeutics Inc.July 2025 Earnings & Smart Money Movement Alerts - Newser
Will Enliven Therapeutics Inc. stock split in the near futureRate Hike & AI Powered Buy and Sell Recommendations - Newser
Sectors Driving Future Growth for Enliven Therapeutics Inc. StockTrade Performance Summary & Low Volatility Stock Suggestions - Newser
Is Enliven Therapeutics Inc. a Top Dividend Stock to Watch in 2025Inflation Watch & Technical Pattern Alert System - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityGap Up & Entry Point Strategy Guides - Newser
Why Enliven Therapeutics Inc. stock attracts strong analyst attentionTrade Analysis Summary & Comprehensive Market Scan Reports - thegnnews.com
Enliven Therapeutics: Strong Financial Foundation and Promising ELVN-001 Development Justify Buy Rating - TipRanks
We're Not Very Worried About Enliven Therapeutics' (NASDAQ:ELVN) Cash Burn Rate - Yahoo Finance
Real time social sentiment graph for Enliven Therapeutics Inc.Trade Analysis Report & Expert Curated Trade Setup Alerts - Newser
Enliven Therapeutics: Cash runway could fund ops into 2029 - BizWest
Enliven Therapeutics: Strong Financial Health and Promising CML Treatment Drive Buy Rating - TipRanks
Enliven Therapeutics shares fall 1.58% intraday after reporting positive Phase 1 clinical trial data for ELVN-001 in CML. - AInvest
BTIG reiterates Buy rating on Enliven Therapeutics stock with $45 target - Investing.com Canada
BTIG reiterates Buy rating on Enliven Therapeutics stock with $45 target By Investing.com - Investing.com South Africa
Enliven Therapeutics Inc. Bounces Off Moving Average SupportJuly 2025 Earnings & Free Daily Entry Point Trade Alerts - metal.it
Enliven Therapeutics Reports Positive Trial Results and Strong Financials - TipRanks
Enliven Posts Loss Beat and Cash Surge - The Motley Fool
Enliven Posts Loss Beat and Cash Surge - Nasdaq
Enliven Therapeutics, Inc Q2 Loss Climbs - Nasdaq
Enliven Therapeutics: A High-Conviction Biotech Play in Precision Oncology - AInvest
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - PR Newswire
Published on: 2025-08-13 08:33:59 - Newser
Unlocking Value Post-Lock-Up: Analyzing Enliven Therapeutics' Recent Equity Raise and Implications for Investor Strategy - AInvest
The Strategic Timing of Enliven Therapeutics' $230M Raise and Lock-Up Expiration: A Playbook for Warrant Holders and Institutional Investors - AInvest
Certain Common Stock of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2025. - MarketScreener
What makes Enliven Therapeutics Inc. stock price move sharplyFree Breakout Confirmation With Entry Tracker - Newser
Enliven Therapeutics' COO Patel Anish sells shares on August 7 at $18.2 and $18.93. - AInvest
Institutional scanner results for Enliven Therapeutics Inc.Asset Growth Pattern and Return Summary - Newser
Enliven Therapeutics (ELVN) Projected to Post Earnings on Tuesday - Defense World
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):